RT Book, Section
A1 Duda, John E.
A2 Watts, Ray L.
A2 Standaert, David G.
A2 Obeso, Jose A.
SR Print(0)
ID 55795913
T1 Chapter 19. Parkinson's Disease: Neuropathology
T2 Movement Disorders, 3e
YR 2012
FD 2012
PB The McGraw-Hill Companies
PP New York, NY
SN 978-0-07-161312-5
LK neurology.mhmedical.com/content.aspx?aid=55795913
RD 2024/04/25
AB From  the  recognition  of  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (MPTP)-induced  parkinsonism  to  the  discovery  of  numerous  genes  responsible  for  rare  Mendelian  forms  of  parkinsonism,  our  understanding  of  the  mechanisms  involved  in  rare  causes  of  parkinsonism  has  exploded  in  the  past  25  years.  It  was  hoped  that  further  understanding  of  the  pathophysiologic  mechanisms  involved  in  these  conditions  would  lead  to  novel  therapeutic  interventions  for  people  afflicted  with  what  is  by  far  the  most  common  form  of  parkinsonism,  Lewy  body  Parkinson's  disease  (hereafter  referred  to  as  PD).  As  clues  to  the  pathophysiology  of  these  other  forms  of  parkinsonism  arose,  cellular  and  animal  models  designed  to  recapitulate  these  mechanisms  were  developed.  These  models  have  enhanced  our  understanding  of  nigrostriatal  degeneration  and  basal  ganglionic  circuitry.